Browse MMP7

Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF00413 Matrixin
PF01471 Putative peptidoglycan binding domain
Function

Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase.

> Gene Ontology
 
Biological Process GO:0007565 female pregnancy
GO:0007568 aging
GO:0009612 response to mechanical stimulus
GO:0009991 response to extracellular stimulus
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030574 collagen catabolic process
GO:0031667 response to nutrient levels
GO:0032963 collagen metabolic process
GO:0042698 ovulation cycle
GO:0043062 extracellular structure organization
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044706 multi-multicellular organism process
GO:0044849 estrous cycle
GO:0048511 rhythmic process
GO:0060135 maternal process involved in female pregnancy
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071496 cellular response to external stimulus
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0017171 serine hydrolase activity
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG hsa04310 Wnt signaling pathway
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-1442490: Collagen degradation
R-HSA-1474290: Collagen formation
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MMP7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MMP7 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16891318GlioblastomaPromote immunityYet again, MP inhibition by the broad spectrum inhibitors GM 6001 or MMP inhibitor III selectively enhanced the expression of MICA and ULBP2 on the surface of LNT- 229 cells but not of other NKG2DL (Fig. 4A). For MICA, this effect was significantly more prominent on control than on TGF-b1/2 siRNA cells. Thus, escape from NKG2D-mediated immune surveillance of malignant gliomas in vivo may be promoted by the inhibition of MICA and ULBP2 expression via an autocrine TGF-beta loop and by MP-dependent shedding from the cell surface.
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MMP7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MMP7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2150.778
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7280.183
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9080.371
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3530.652
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.010.994
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8020.649
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3870.701
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4820.739
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4760.75
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 483.260.201
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.0220.447
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.0920.00424
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MMP7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610100-1000.143
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MMP7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MMP7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMMP7
Namematrix metallopeptidase 7
Aliases PUMP-1; matrilysin; MPSL1; matrix metalloproteinase 7 (matrilysin, uterine); MMP-7; matrin; matrix metallope ......
Chromosomal Location11q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MMP7 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MMP7.
ID Name Drug Type Targets #Targets
DB00786MarimastatSmall MoleculeMMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......23
DB08170(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDESmall MoleculeMMP71
DB08489N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDESmall MoleculeMMP71
DB084935-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACIDSmall MoleculeMMP71